AIDS-related Peripheral/Systemic Lymphoma Clinical Trial
Official title:
A Phase I Trial of Combination Bryostatin-1 and Vincristine in HIV-Related B-cell Neoplasms
Phase I trial to study the effectiveness of bryostatin 1 plus vincristine in treating patients who have recurrent or refractory lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help vincristine kill more cancer cells by making them more sensitive to the drug
OBJECTIVES:
I. Determine the maximum tolerated dose of bryostatin 1 when administered with vincristine
in patients with recurrent or refractory HIV-related B-cell lymphoma.
II. Determine the toxicity profile of this regimen in these patients. III. Determine the
objective response and survival of these patients treated with this regimen.
IV. Determine the immunomodulatory effects of this regimen on interleukin-2 (IL-2), IL-2
receptor, and IL-6 cytokine levels in these patients.
V. Determine the effect of this regimen on CD4+ lymphocyte count and HIV load in these
patients.
VI. Determine the effect of this regimen on the human herpes virus-8 load in these patients
with body cavity-based lymphoma.
OUTLINE: This is a multicenter, dose-escalation study of bryostatin 1.
Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5
minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in
the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of bryostatin 1 until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
patients experience dose-limiting toxicity.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01775475 -
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
|
Phase 2 | |
| Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
| Terminated |
NCT00096005 -
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
| Completed |
NCT00049036 -
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Completed |
NCT01158274 -
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00036855 -
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
|
Phase 1 | |
| Completed |
NCT00003970 -
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT01769911 -
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
|
N/A | |
| Completed |
NCT00077155 -
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT00025415 -
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
|
Phase 1 | |
| Completed |
NCT00005811 -
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
|
Phase 2 |